Biocytogen Announces U.S. Food and Drug Administration IND Clearance for NEOK Bio’s NEOK002 Targeting Solid Tumors

Biocytogen Announces U.S. Food and Drug Administration IND Clearance for Partner NEOK Bio’s NEOK002 in Solid Tumor Indications Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has announced a significant regulatory milestone achieved…

Read MoreBiocytogen Announces U.S. Food and Drug Administration IND Clearance for NEOK Bio’s NEOK002 Targeting Solid Tumors

WuXi Biologics Reports Record 2025 Annual Results, Fueled by Operational Excellence and Digital-Native Innovation

WuXi Biologics Announces Record 2025 Annual Results, Fueled by Operational Excellence and Digital-Native Infrastructure WuXi Biologics has reported strong financial and operational performance for 2025, marking a year of significant…

Read MoreWuXi Biologics Reports Record 2025 Annual Results, Fueled by Operational Excellence and Digital-Native Innovation